FROM OUR EXPERTS
Nonsteroidal antiinflammatory drugs (NSAIDs) still remain one of the most commonly used drugs for joint pain from osteoarthritis (OA). Changes have come about over the years to improve these drugs. Reducing side effects such as stomach bleeds and kidney problems has brought a whole new generation of NSAIDs to the market. In this article, doctors from NYU Hospital for Joint Diseases in New York review current trends with NSAID use. Choosing the right NSAID for each patient is the first step. Acetaminophen (Tylenol®) is still the first choice for mild OA. Tylenol is a pain reliever but not an NSAID. When Tylenol® is not effective, an NSAID may be needed to control pain and inflammation. Aspirin used to be the most popular NSAID. But aspirin use in some people can result in ulcers, GI bleeding, and kidney failure. Scientists discovered that certain enzymes called cyclooxygenase (COX) were part of the problem. A new group of NSAIDs was developed to inhibit or stop one specific enzyme (COX-2...
in The Daily Mail highlighted a study conducted by the
University of Tampere in Finland that suggests that men who take
daily doses of pain medications, including ibuprofen, are at a
higher risk of erectile dysfunction.
Urologist Dr. David Knowles comments on the study and tells us
what this research can reveal about the causes of erectile
Dr. David Knowles:
There is a new study out of University of Tampere in Finland
that came to the conclusion that Aspirin and other
anti-inflammatory medications are related to erectile dysfunction
(ED). This has made some people come to the assumption that these
medications may cause ED. This is NOT the case. This study was not
designed to determine a cause and effect. They simply collected
data to see if there were any associations. They found an
association between people who take these medications and ED. If
you think about this it makes great sense. The two most common
reasons to take aspirin and other anti-inflam...
Merck, the manufacturer of Vioxx recently announced that preliminary analyses of its MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-Term Program), show that patients with osteoarthritis and rheumatoid arthritis have similar cardiovascular outcomes between its experimental COX-2 inhibitor drug, Arcoxia, and diclofenac, a traditional nonsteroidal anti-inflammatory drug (NSAID). Merck is developing Arcoxia as the successor to Vioxx.
The MEDAL program is a group of three studies that began in 2002 and enrolled over 34,000 patients. The research studied the effects of Arcoxia 60 mg or 90 mg on osteoarthritis and rheumatoid arthritis. The preliminary analysis of the study revealed that the incidence of patients withdrawing from the trial due to hypertension-related adverse events was significantly higher for Arcoxia than for diclofenac. Also, the incidence of discontinuations due to edema-related adverse events and congestive heart failure was significantly higher only for Ar...
You should know
Answers to your question are meant to provide general health information but should not replace medical advice you receive from a doctor. No answers should be viewed as a diagnosis or recommended treatment for a condition. Content posted by community members does not necessarily reflect the views of Remedy Health Media, which also reserves the right to remove material deemed inappropriate.